Barclays PLC Acquires 36,316 Shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM)

Barclays PLC increased its holdings in shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM) by 1,428.1% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 38,859 shares of the company’s stock after purchasing an additional 36,316 shares during the period. Barclays PLC owned 0.13% of Eliem Therapeutics worth $198,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the business. Janus Henderson Group PLC boosted its position in Eliem Therapeutics by 10.8% during the 3rd quarter. Janus Henderson Group PLC now owns 3,606,495 shares of the company’s stock valued at $18,303,000 after acquiring an additional 352,507 shares in the last quarter. Affinity Asset Advisors LLC bought a new stake in Eliem Therapeutics during the second quarter valued at about $11,878,000. Ally Bridge Group NY LLC grew its stake in Eliem Therapeutics by 145.9% in the third quarter. Ally Bridge Group NY LLC now owns 1,229,292 shares of the company’s stock valued at $6,257,000 after purchasing an additional 729,292 shares during the last quarter. Point72 Asset Management L.P. bought a new position in Eliem Therapeutics in the third quarter worth about $3,008,000. Finally, State Street Corp lifted its position in shares of Eliem Therapeutics by 433.9% during the third quarter. State Street Corp now owns 315,036 shares of the company’s stock valued at $1,604,000 after buying an additional 256,029 shares during the last quarter. 69.76% of the stock is owned by hedge funds and other institutional investors.

Eliem Therapeutics Stock Up 8.7 %

Shares of Eliem Therapeutics stock opened at $2.25 on Tuesday. The company has a market cap of $66.94 million, a P/E ratio of -4.25 and a beta of -0.39. The firm’s 50 day moving average price is $2.97 and its 200-day moving average price is $5.36. Eliem Therapeutics, Inc. has a 52-week low of $2.35 and a 52-week high of $11.55.

About Eliem Therapeutics

Eliem Therapeutics, Inc, a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.